Landscape Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Landscape Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-178,150	Closed	-$1.27M	–	841
2022 Q3	$1.27M	Sell	178,150 -90,775	-34%	-$855K	0.17%	112
2022 Q2	$2.18M	Buy	268,925 +92,583	+53%	+$814K	0.29%	72
2022 Q1	$2.45M	Buy	176,342 +111,443	+172%	+$1.75M	0.31%	72
2021 Q4	$1.82M	Buy	+64,899	New	+$1.99M	0.26%	84
2021 Q1	–	Sell	-17,623	Closed	-$1.04M	–	421
2020 Q4	$1.04M	Sell	17,623 -6,043	-26%	-$312K	0.17%	123
2020 Q3	$1.15M	Buy	+23,666	New	+$995K	0.21%	96
2019 Q3	–	Sell	-6,543	Closed	-$316K	–	631
2019 Q2	$316K	Buy	+6,543	New	+$290K	0.03%	516

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BWLSA

Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Landscape Capital Management's ADPT Position: Q4 2022 in Review

Landscape Capital Management sold out of Adaptive Biotechnologies (ADPT) in Q4 2022, closing a stake of 178,150 shares — an estimated $1.27M sold.

Landscape Capital Management first reported a position in ADPT in Q2 2019 and held it in 7 quarters. The position peaked at $2.45M in Q1 2022. 223 funds tracked by Wall St. Rank hold ADPT as of Q4 2022.

Landscape Capital Management reported no remaining Adaptive Biotechnologies position as of Q4 2022 after selling out during the quarter.
Landscape Capital Management sold 178,150 Adaptive Biotechnologies shares in Q4 2022, an estimated $1.27M.
Landscape Capital Management first reported a position in Adaptive Biotechnologies in Q2 2019 and held it in 7 quarters.
Landscape Capital Management's Adaptive Biotechnologies position peaked at $2.45M in Q1 2022.
223 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2022.

Based on Landscape Capital Management's 13F filing for Q4 2022, filed 9 Feb 2023.